<DOC>
	<DOCNO>NCT00114153</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , carboplatin capecitabine , work different way stop growth tumor cell , either kill cell stop divide . Radiation therapy use high-energy x-ray kill tumor cell . Giving chemotherapy together radiation therapy may kill tumor cell . PURPOSE : This phase I trial study side effect best dose capecitabine give together carboplatin follow radiation therapy treat patient stage III stage IV head neck cancer .</brief_summary>
	<brief_title>Carboplatin , Capecitabine , Radiation Therapy Treating Patients With Stage III Stage IV Head Neck Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine maximum tolerate dose ( MTD ) capecitabine administer carboplatin induction chemotherapy patient stage III-IVB squamous cell carcinoma head neck . - Determine MTD capecitabine administer concurrent carboplatin intensity-modulated radiotherapy patient . - Determine toxicity regimen patient . Secondary - Determine , preliminarily , tumor response patient treat regimen . - Determine quality life patient treat regimen . OUTLINE : This dose-escalation study capecitabine . - Induction chemotherapy : Patients receive carboplatin IV day 1 , 8 , 15 , 22 , 29 , 36 oral capecitabine twice daily day 1-14 22-35 . - Concurrent chemoradiotherapy : Beginning 2 week completion induction chemotherapy , patient receive carboplatin capecitabine induction chemotherapy . Patients also undergo intensity-modulated radiotherapy ( IMRT ) daily day 1-5 , 8-12 , 15-19 , 22-26 , 29-33 non-IMRT boost daily day 36-40 43-47 . Treatment continue absence disease progression unacceptable toxicity . Within 4-8 week completion concurrent chemoradiotherapy , patient achieve clinical complete response medically operable resectable persistent recurrent disease undergo neck dissection ( salvage surgery ) . Cohorts 3-6 patient receive escalate dos capecitabine ( induction chemotherapy concurrent chemoradiotherapy ) maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . Quality life assess baseline , completion induction chemotherapy , 1 week 3 , 6 , 12 month completion concurrent chemoradiotherapy . After completion study therapy , patient follow monthly 3 month every 3 month 1 year . PROJECTED ACCRUAL : Approximately 6-48 patient accrue study .</detailed_description>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm squamous cell carcinoma head neck , include 1 follow type : Oral cavity Oropharynx Hypopharynx Clinical stage IIIIVB ( T2T4 , N0N3 , M0 ) disease Measurable disease physical exam , endoscopy , and/or CT scan MRI Residual measurable disease fine needle aspiration , core needle biopsy , incisional excisional biopsy primary tumor No evidence distant metastasis ( M1 ) PATIENT CHARACTERISTICS : Age 18 Performance status Zubrod 01 Life expectancy Not specify Hematopoietic Absolute neutrophil count &gt; 1,500/mm^3 Platelet count &gt; 100,000/mm^3 Hemoglobin &gt; 9 g/dL No uncontrolled coagulopathy Hepatic AST &lt; 2 time normal Alkaline phosphatase &lt; 2 time normal Bilirubin normal Renal Creatinine &lt; 2.0 mg/dL OR Creatinine clearance &gt; 50 mL/min Cardiovascular No congestive heart failure No symptomatic coronary artery disease No uncontrolled cardiac arrhythmia No myocardial infarction within past year No clinically significant cardiac disease Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception least 30 day completion study treatment Nutritional general physical condition must compatible propose study treatment Mentally reliable No preexist peripheral neuropathy &gt; grade 1 No history hypersensitivity fluorouracil , capecitabine , carboplatin No active infection No malignancy within past 5 year except nonmelanoma skin cancer No major medical , psychiatric , neurologic illness would preclude study participation give informed consent PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy More 5 year since prior chemotherapy Endocrine therapy Not specify Radiotherapy No prior radiotherapy head neck tumor No prior radiotherapy region plan study radiotherapy field Surgery Recovered prior surgery No unhealed surgical wound Other More 4 week since prior investigational drug No concurrent warfarin , diphenylhydantoin , fluconazole unless willing undergo careful monitoring appropriate dose adjustment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2007</verification_date>
	<keyword>stage III squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage III squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage III squamous cell carcinoma oropharynx</keyword>
	<keyword>stage IV squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage IV squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage IV squamous cell carcinoma oropharynx</keyword>
</DOC>